{"podcast":{"title":"PsychRounds: The Psychiatry Podcast","slug":"psychrounds-the-psychiatry-podcast-6714703","podcast_index_feed_id":6714703,"rss_url":"https://anchor.fm/s/eb936048/podcast/rss","website_url":"https://podcasters.spotify.com/pod/show/psychrounds","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/39423042/39423042-1699304839414-787f9f0b04889.jpg","author":"Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley Miller","episode_count":114,"summary":"Welcome to Psych Rounds, the podcast tailored for psychiatry residents and students. Join us, three psychiatric resident physicians, as we delve into quick insights, interviews, and practical tips essential for educational practice. Subscribe for a straightforward yet informal approach to psychiatric knowledge. Contact us: psychroundspodcast@gmail.com Instagram: https://www.instagram.com/psychrounds/","last_synced_at":"2026-07-22T16:18:47.387705+00:00","page_url":"https://stenobird.com/podcast/psychrounds-the-psychiatry-podcast-6714703"},"episode":{"title":"VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)","slug":"vmat2-inhibitors-valbenazine-ingrezza-and-deutetrabenazine-austedo","published_at":"2026-03-21T17:57:26+00:00","page_url":"https://stenobird.com/podcast/psychrounds-the-psychiatry-podcast-6714703/vmat2-inhibitors-valbenazine-ingrezza-and-deutetrabenazine-austedo","show_page_url":"https://stenobird.com/podcast/psychrounds-the-psychiatry-podcast-6714703","url":"https://podcasters.spotify.com/pod/show/psychrounds/episodes/VMAT2-Inhibitors-Valbenazine-Ingrezza-and-Deutetrabenazine-Austedo-e3g8odb","audio_url":"https://anchor.fm/s/eb936048/podcast/play/116727659/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-2-11%2F419751627-44100-2-e2a85ebd5c645.m4a","summary":"Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: https://pubmed.ncbi.nlm.nih.gov/41626799/ https://www.ncbi.nlm.nih.gov/books/NBK548187/ https://pubmed.ncbi.nlm.nih.gov/41626799/","meta_description":"Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabena…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1039,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/psychrounds-the-psychiatry-podcast-6714703/episodes/vmat2-inhibitors-valbenazine-ingrezza-and-deutetrabenazine-austedo/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/psychrounds-the-psychiatry-podcast-6714703/vmat2-inhibitors-valbenazine-ingrezza-and-deutetrabenazine-austedo.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}